Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

rtain

investments.

(6) To reflect the tax effect of pre-tax adjustments at the applicable tax

rates and certain other tax adjustments primarily related to changes

in valuation allowances and other changes in tax assets and

liabilities.

(7) To exclude the DoD Tricare program reversal as a result of the U.S.

Court of Appeals September 2006 ruling.

(8) To exclude charges associated with the settlement of the PROVIGIL

patent litigation ($6.0 million) and employee severance costs

associated with the European integration and restructuring ($4.0

million).

(9) To exclude charges related to the impairment of an intangible asset.

(10) To exclude the write-off of deferred debt issuance costs related to

the Zero Coupon convertible subordinated notes.

(11) Amounts shown no longer exclude the impact of SFAS 123(R). The

earnings press release issued on November 2, 2006 reflected

adjustments of $11.6 million in each of Research and development and

Selling, general and administrative expenses and $8.8 million in

Income tax expense related to SFAS 123(R).

CEPHALON, INC. AND SUBSIDIARIES

"ADJUSTED" CONSOLIDATED SALES DETAIL *

(In thousands)

(Unaudited)

Three Months Ended

September 30,

2007

United

States Europe Total

Sales:

PROVIGIL $202,202 $14,904 $217,106

GABITRIL 12,952 881 13,833

CNS 215,154 15,785 230,939

ACTIQ
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
(Date:7/24/2014)... -- Research and Markets has announced the ... report to their offering.  ... in vitro growth of plant or animal cells for ... production. Cell culture is a crucial step in tissue ... culture consumables are necessary for the in vitro production ...
(Date:7/24/2014)... 2014 SRI International has been awarded a ... of Allergy and Infectious Diseases (NIAID), part of the ... potential therapies for HIV infection and AIDS. The contract ... AIDS and the complications and opportunistic infections associated with ... transmission of HIV. According to the ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... WAYNE, Pa., May 15 Escalon Medical Corp.,(Nasdaq: ... quarter and,nine months ended March 31, 2008., For ... 18% to,$8,139,000 compared with $6,900,000 reported in the same ... sales in each of the,Company,s business units., Net ...
... biotechnology company that is focused on the development of,autologous (patient-derived) ... heart damage, today announced financial results for,the quarter ended March ... 19, 2008, the Company completed its initial public offering ... of approximately $5.8 million. The net ...
... Advisory Panel reacts to CMS final rule; ... identifies challenges, recommends strategies, ... Inc. and,the International Expert Wound Care Advisory Panel ... Improve Pressure,Ulcer Prevention and Treatment: Implications of the ...
Cached Biology Technology:Escalon(R) Reports Third Quarter Fiscal 2008 Results 2Escalon(R) Reports Third Quarter Fiscal 2008 Results 3Escalon(R) Reports Third Quarter Fiscal 2008 Results 4Escalon(R) Reports Third Quarter Fiscal 2008 Results 5Escalon(R) Reports Third Quarter Fiscal 2008 Results 6Escalon(R) Reports Third Quarter Fiscal 2008 Results 7Escalon(R) Reports Third Quarter Fiscal 2008 Results 8Bioheart, Inc. Announces Financial Results for First Quarter 2008 2Bioheart, Inc. Announces Financial Results for First Quarter 2008 3Bioheart, Inc. Announces Financial Results for First Quarter 2008 4Bioheart, Inc. Announces Financial Results for First Quarter 2008 5Bioheart, Inc. Announces Financial Results for First Quarter 2008 6Bioheart, Inc. Announces Financial Results for First Quarter 2008 7International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 2International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 3
(Date:7/24/2014)... study has identified two factors that characterize sustainable ... production of highly qualified physics teachers. Specifically, one ... physics teacher education in combination with institutional motivation ... viable. Science, Technology, Engineering and Math (STEM) teacher ... study points the way for institutions seeking to ...
(Date:7/24/2014)... team of researchers has developed a new nanoscale agent ... method for assessing the function and properties of the ... diagnosis and treatment of gut diseases. , ... syndrome and inflammatory bowel disease all occur in the ... patients with diseases such as diabetes and Parkinson,s. ...
(Date:7/24/2014)... Forest is a hotspot of biodiversity and one of ... and toads) in the world. However, current levels of ... years has been an increase in the description of ... advance of molecular techniques and availability of samples for ... of samples for molecular and morphological analysis, researchers from ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2New imaging agent provides better picture of the gut 2A tiny new species of frog from Brazil with a heroic name 2
... acne (Propionibacterium acnes) will be the topic of the Denver ... University. As well as acne, this bacterium is responsible for ... diagnosis. Why are we not more aware of this versatile ... and boost the immune system: , Probiotics can ...
... Most college students in the United States do ... an essential skill in understanding the causes and ... the January issue of BioScience . The ... from Michigan State University, calls for a new way ...
... Scientists at Rothamsted Research, United Kingdom, in collaboration with ... Areas (ICARDA), Syria have developed a method of accounting ... trend refers to the variations in crop yield and ... trial. Usually plant breeders will grow several replicate ...
Cached Biology News:Probiotics, prebiotics and biofuel-producing bacteria 2College students lack scientific literacy, study finds 2
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
... Protein size: 325 Accession ... using peptide based assay: 1:1562500 ... 1.0g/ml in 5% skim milk / ... should be diluted in 1: 50,000 - ...
... 4503277 Accession Number: NP_001912.1 ... the nucleotide substrate for thymidylate synthetase. ... O = dUMP + NH 3 ... the Diseases: Benign Tumor; Leukemia; Escherichia ...
Active GST Protein...
Biology Products: